CN106801043B - A kind of recombination transaminase and its preparation method and application - Google Patents
A kind of recombination transaminase and its preparation method and application Download PDFInfo
- Publication number
- CN106801043B CN106801043B CN201611239147.1A CN201611239147A CN106801043B CN 106801043 B CN106801043 B CN 106801043B CN 201611239147 A CN201611239147 A CN 201611239147A CN 106801043 B CN106801043 B CN 106801043B
- Authority
- CN
- China
- Prior art keywords
- recombination
- transaminase
- transaminase mutant
- genetic engineering
- recombination transaminase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/001—Amines; Imines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention discloses a kind of recombination transaminases and its preparation method and application.A kind of recombination transaminase mutant of high activity, amino acid sequence is as shown in SEQ ID NO.2, and encoding gene is as shown in SEQ ID NO.1.A method of the recombination transaminase is prepared, the genetic engineering bacterium of above-mentioned encoding gene is contained including fermented and cultured, and collect and preparation and reorganization transaminase.Recombination transaminase of the present invention is applied to asymmetric syntheses chirality aminated compounds, especially for synthesizing sitagliptin intermediate (R) -3- amino -4- (2,4,5- trifluorophenyl)-methyl butyrate.Enzyme according to the present invention has excellent stereoselectivity, regioselectivity and catalysis activity, and the reaction of its catalysis is mild, and the yield of reaction conversion ratio and product is high, with good application prospect.
Description
Technical field
The invention belongs to technical field of bioengineering, and in particular to a kind of recombination transaminase and its preparation method and application.
Background technique
Diabetes are the chronic progressive diseases of a kind of whole body caused by human body own metabolism disorder, are by insulin secretion
Caused by insufficient or insulin action obstacle.Diabetes are usually concurrent with coronary heart disease, cranial vascular disease, nephrosis, lower limbs necrosis etc.
Disease is a kind of frequently-occurring disease of complexity.Whole world maturity-onset diabetes number of patients is up to 4.22 hundred million at present, it is contemplated that 2025, the whole world will
There are more than 700,000,000 people to suffer from diabetes.
Diabetes are broadly divided into two kinds of I type and II type, and wherein type II diabetes is Non-Insulin Dependent Diabetes Mellitus, be by
Insulin resistance or islet beta cell function, which are damaged, to be caused, and patient accounts for 90% of diabetic or more.II type for the treatment of sugar at present
There are many drugs for urinating disease, as sulfonylurea, biguanides, thiazolidinediones, alpha-glucosidase restrainer, benzoic acid are derivative
Species etc. influence patient due to there are side effect and adhere to medication, preferable blood glucose is not achieved although blood sugar reducing function is ideal
Control purpose.
Dipeptidyl peptidase-IV (DPP-IV) can be cracked including glucagon-like-peptide-1 (GLP-1) and Gastric inhibitory polypeptide (GIP)
A variety of peptide hormones inside, and the two and type II diabetes have close ties.DPP-IV inhibitor can pass through inhibition
DPP-IV reduces the degradation of GLP-1, increases the plasma concentration of GLP-1, so as to improve postprandial blood sugar.In addition, DPP-IV inhibitor
It may also suppress other peptides of the participations such as GIP, pituitary adenylyl cyclase activating polypeptide and gastrin releasing peptide adjusting blood glucose
Degradation.
In October, 2006, Food and Drug Adminstration of the US (FDA) ratify sitagliptin phosphate monohydrate
(Sitagliptin, trade name Januvia) is for treating type II diabetes.Sitagliptin is first for treating II type sugar
Urinate disease dipeptidyl peptidase (DPP-IV) inhibitor class drug, can inhibit glucagon secretion and beta Cell of islet proliferation and
It is horizontal to improve glucose-tolerant, blood sugar reducing function is relatively mild, does not cause patient's oedema and weight gain, leads to the wind of hypoglycemia
Danger is smaller, and the side effects such as nothing is put on weight, Nausea and vomiting.Sitagliptin is used alone or shares with other antidiabetic drugs,
It can reach the purpose of hypoglycemic.
Sitagliptin Chinese is 7- [(3R) -3- amino -1- oxo -4- (2,4,5- trifluorophenyl) butyl] -5,
6,7,8- tetrahydro -3- (trifluoromethyl) -1,2,4- triazoles [4,3- α] pyrazoles phosphoric acid (1:1) monohydrate, molecular formula are
C16H15F6N5O, relative molecular mass 407.31, No. CAS is 654671-77-9.
At present there are many synthetic methods of sitagliptin, wherein yield it is higher be United States Merck company synthetic method
(WO2004085378, WO2005020920): asymmetric hydrogenation is carried out to unprotected enamine with chirality rhodium catalyst, is reacted
Total recovery is higher, is 74.5%, and lower production costs.But the resulting product optical purity of the route is lower (ee 97%), needs
Crystallization concentration can just obtain optically pure sitagliptin, and reaction needs high-pressure hydrogenation (250psi), to consersion unit require compared with
It is high.
That there are reaction routes is long for chemical synthesis sitagliptin and its intermediate, need using toxic raw materials, product yield and
The disadvantages of optical purity is low, severe reaction conditions;And Enzyme catalyzed synthesis sitagliptin intermediate is mild with reaction condition, reaction
Specificity is strong, side reaction is few, the yield of product and optical purity are high, can be easily separated the advantages that purifying, before having preferable application
Scape.The present invention develops the recombination transaminase that a kind of catalytic activity is high, enantioselectivity is good, substrate tolerance is good, can be used for urging
It is combined to chiral amine compound, especially catalyzes and synthesizes sitagliptin intermediate (R) -3- amino -4- (2,4,5- trifluorophenyl) -
Methyl butyrate.
Summary of the invention
The technical problem to be solved by the present invention is to the long, needs for current sitagliptin and its intermediate synthetic route
The disadvantages of using toxic raw materials, product yield and chiral purity is low, severe reaction conditions, provides that a kind of catalytic activity is high, mapping
The recombination transaminase that selectivity is good, substrate tolerance is good, the encoding gene of the transaminase, the recombinant expression containing the gene carry
Body, recombinant expression transformants and preparation method thereof and the recombination transaminase mutant are prepared in chiral amine compound in catalysis
Application.Particularly, which is used for sitagliptin intermediate (R) -3- amino -4- (2,4,5- trifluorophenyl) -
The preparation of methyl butyrate.
The purpose of the present invention can be achieved through the following technical solutions:
A kind of recombination transaminase mutant of high activity, the Aspergillus terreus encoded with gene shown in SEQ ID NO.3
(Aspergillus terreus) NIH2624 wild type transaminase is the enzyme that sets out, will be in the enzyme active center and guiding activity
It is higher that the amino acid residue in some sites in the hydrophobic channel of the heart sports the catalytic activity that other amino acid residues obtain
Recombination transaminase mutant;The activated centre is defined as substrate binding site nearby aboutDiameter of Spherical Volume;
Any one of described preferred SEQ ID NO.2 2 of recombination transaminase variant amino acid sequence.
Nucleic acid source shown in SEQ ID NO.3 is in Aspergillus terreus (Aspergillus terreus) in the present invention
NIH2624.Nucleic acid shown in SEQ ID NO.3 of the present invention can be from Aspergillus terreus (Aspergillus terreus)
It separates and obtains in the genome of NIH2624, it can also from the recombinant expression carrier containing nucleic acid shown in SEQ ID NO.3 or again
It separates and obtains in group transformant, artificial synthesized can also obtain.
A kind of gene encoding recombination transaminase mutant of the present invention, nucleotide sequence are selected from SEQ ID
NO.1。
A kind of recombinant expression carrier comprising recombination transaminase mutant code gene of the present invention.It can pass through this
The nucleic acid sequence of recombination aminotransferase gene of the invention is connected to built-up on various carriers by field conventional method.Described
Carrier can be the various carriers of this field routine, such as commercially available plasmid, bacteriophage or viral vectors, preferred plasmid
pET21a。
A kind of recombinant expression comprising recombination transaminase mutant code gene or its recombinant expression carrier of the invention turn
Change body, the preferred escherichia coli of the present invention (Escherichia coli) BL21 (DE3).Aforementioned recombinant expression plasmid is converted
Into escherichia coli (Escherichia coli) BL21 (DE3), currently preferred genetic engineering bacterium can be obtained.
A method of it preparing the recombination transaminase, including the fermented and cultured genetic engineering bacterium, and collects and make
Standby recombination transaminase.
The step that the method includes under centainly production tank fermentation condition, carrying out recombinating transaminase described in preparation of industrialization
Suddenly;The production tank fermentation condition is preferred: 35% or more DO, air mass flow 1:1.5vvm.
Recombination transaminase of the present invention is applied to asymmetric syntheses chirality aminated compounds, especially for synthesizing west
Ta Lieting intermediate (R) -3- amino -4- (2,4,5- trifluorophenyl)-methyl butyrate.
The transaminase-catalyzed reaction of present invention recombination is as follows:
It is preferred that: in the reaction solution of pH 6.5~7.5, in the presence of pyridoxime 5-phosphate, in recombination of the present invention
Under the effect of transaminase mutant, reduction is catalyzed as substrate enantioselective enzyme using compound A and prepares optics chiral amine compound
Wherein, R is alkyl or substituted heteroaryl, preferably CnH2n+1And benzyl, wherein n is selected from 1~8 integer.
A kind of synthetic method of sitagliptin, reaction route are as follows:
The utility model has the advantages that
The present invention by chemistry, molecular biology, bioinformatics and high-throughput screening method, exploitation to it is a kind of with compared with
The recombination transaminase mutant of high specific (enantiomeric excess value > 99.5%) and preferably catalytic activity, for catalyzing and synthesizing hand
Property amine compounds.The co-factor of recombination transaminase of the invention is pyridoxime 5-phosphate PLP.
Enzyme according to the present invention have excellent stereoselectivity, regioselectivity and catalysis activity, and its catalysis
Reaction is mild, and the yield of reaction conversion ratio and product is high, with good application prospect.
Specific embodiment
The foundation of 1 genetic engineering bacterium of embodiment
The gene order of Aspergillus terreus (the Aspergillus terreus NIH2624) transaminase included according to Genbank
(NCBI accession number: XM_001209325.1), the artificial synthesized genetic fragment extend segment (the segment two sides by PCR amplification
Add I incision enzyme gene segment of Nde I and BamH), nucleotide sequence is as shown in SEQ ID NO.3.And utilize Nde I and BamH I
Gene is inserted into pET21a plasmid by restriction enzyme site, and the carrier after connection is transferred to foundation in e. coli bl21 (DE3) and is turned
Adnosine deaminase genetic engineering bacterium.The wherein primer of PCR amplification aminotransferase gene are as follows: forward primer F1:GGGGCCATATGGCCTCCATG
GACAAAGTCTTT (SEQ ID NO.4), reverse primer R1:GGGCCGGATCCCGTTATAATCAATCTCGAAGC (SEQ ID
NO.5)。
The acquisition of 2 transaminase mutant gene of embodiment
This research and utilization fallibility PCR method has carried out protein engineering transformation to transaminase.Fallibility PCR is using DNA
When polymerase carries out target gene amplification, by adjusting reaction condition, magnesium ion concentration is such as improved, manganese ion is added, changes body
Four kinds of dNTPs concentration or utilization low fidelity archaeal dna polymerase etc. in system, to change the frequency of mutation in amplification procedure, thus
It is randomly incorporated into mutation into target gene with certain frequency, obtains the random mutant of protein molecule.This research is using guarantor
It really spends lower polymerase to be easy to mix the principle of random mutation into amplified production under certain measures, while utilizing Mn2+
Substitute natural confactor Mg2+Increase fallibility probability.
50 μ l PCR reaction systems are as follows: 10 × amplification buffer 5 μ l, 4 kinds of each 4 μ l of dNTP mixture (2.5mmol/L) draw
Each 50pmol of object, 1.5 μ g, Taq archaeal dna polymerase of template DNA 0.5 μ L, Mg2+2mmol/L adds distilled water to 50 μ l.
PCR amplification program are as follows: 94 DEG C of initial denaturations 5min, 94 DEG C of denaturation 45s, 55 DEG C of denaturation 30s, 72 DEG C of denaturation 120s, into
Row 30 circulations;Continue to extend 10min at 72 DEG C, is cooled to 4 DEG C.The genetic fragment of amplification is after detecting with 1% agarose
Gel electrophoresis recycling, and amplified production is purified, remove extra primer.
Experiment flow
PCR amplification aminotransferase gene and gene is inserted using Nde I and I restriction enzyme site of BamH according to the method for embodiment 1
Enter into pET21a plasmid, as gene mutation template;
The gene of fallibility PCR amplification transaminase, genetic fragment links to pET21a carrier after amplification, by the carrier after connection
It is transferred in e. coli bl21 (DE3) and establishes aminotransferase gene mutant library;It is host using e. coli bl21 (DE3),
PET21a plasmid is carrier, expression extension transaminase, high flux screening high activity mutant strain;To high activity transaminase base after mutation
Because being identified.The nucleic acid sequence of the high activity transaminase mutant gene filtered out is as shown in SEQ ID NO.1.
Aminotransferase gene primer are as follows: forward primer F1:GGGGCCATATGGCCTCCATGGACAAAGTCTTT (SEQ ID
NO.4), reverse primer R1:GGGCCGGATCCCGTTATAATCAATCTCGAAGC (SEQ ID NO.5).
The genetic engineering bacterium for expressing the transaminase mutant is constructed by 1 the method for embodiment.
After obtaining mutant sequence, I He of Nde is utilized after the gene order can also be synthesized by chemical synthesis mode
Gene is inserted into pET21a plasmid by I restriction enzyme site of BamH, then converts Escherichia coli building genetic engineering bacterium.
It is prepared by the shaking flask of 3 transaminase of embodiment
Embodiment 1, embodiment 2 are constructed into resulting recombination bacillus coli and are seeded to 50mL respectively containing ampicillin (100
μ g/mL) LB culture medium (peptone 10g/L, yeast extract 5g/L, NaCl 10g/L, pH7.2) in, in 37 DEG C, 200rpm's is shaken
Shaken cultivation 16 hours or more in bed.2mL bacterial culture fluid of transferring is cultivated in LB of the 50mL containing chloramphenicol (or ampicillin)
In base, it is placed in shaken cultivation under similarity condition, light absorption value of the Timing measurement bacterium solution at 600nm is to monitor thalli growth density.
When 600 value of OD of bacterium solution is in 0.6-0.8, inducer IPTG to final concentration of 0.2mmol/L, 30 DEG C of inducing expressions 12 are added
Hour or more.Thallus is collected by centrifugation (5000rpm, 15min, 4 DEG C) after expression, and with phosphate buffer (pH7.2,50mM)
Cleaning twice, is scattered in the buffer being equally pre-chilled, ultrasonication is carried out in ice-water bath.It is centrifuged (8000rpm, 30min, 4
DEG C) supernatant is collected, concentration, freeze-drying obtain recombination transaminase or recombinate the crude powder of transaminase mutant.
The measurement of the recombination aminotransferase activity of embodiment 4
With 3- carbonyl -4- (2,4,5- trifluorophenyl) methyl butyrate for substrate, HPLC detects recombination prepared by embodiment 3 and turns
Adnosine deaminase activity, so that the genetic engineering bacterium with highest transaminase enzyme activity can be expressed by filtering out.It is efficient using Shimadzu LC-20AT
Liquid chromatograph is equipped with C18 column (150mm*4.6mm, 5um), 0.1% trifluoroacetic acid aqueous solution of mobile phase-methanol (40:60),
Detection wavelength 254nm, 30 DEG C of column temperature, flow velocity 1.0mLmin-1。
Testing conditions are as follows: reaction system total volume 2mL, wherein including 0.5-50 μm of ol/L substrate, 200 μ L 1mol/L are different
Propylamin hydrochloride, 100 μm of ol pyridoxime 5-phosphate, 5%-25% (v/v) DMSO, 500 μ L enzyme solutions, 45 DEG C of reaction 30min are surveyed
Determine the consumption and product (R) -3- amino -4- (2,4,5- trifluoro of substrate 3- carbonyl -4- (2,4,5- trifluorophenyl) methyl butyrate
Phenyl)-methyl butyrate production quantity.
Enzyme activity unit (U) is defined as: under the above-described reaction conditions, catalysis generates 1 μm of ol (R) -3- amino-per minute
Enzyme amount needed for 4- (2,4,5- trifluorophenyl)-methyl butyrate or per minute 1 μm of ol substrate 3- carbonyl -4- (2,4,5- tri- of consumption
Fluorophenyl) enzyme amount needed for methyl butyrate.
The enzyme activity for measuring recombination transaminase mutant is 926.2U/L, than original enzyme activity (NCBI accession number: XM_
001209325.1) 1.1 times are improved.
Embodiment 5 recombinates the fermentation preparation of transaminase
Fermentation medium components are as follows: ammonium sulfate 0.76g/L, ironic citrate 0.06mg/L, NaCl 10.5g/L, phosphoric acid hydrogen two
Potassium 12.2g/L, potassium dihydrogen phosphate 6.1g/L, yeast extract 11.5g/L, peptone 7.1g/L, glycerol 17.3g/L, ammonium molybdate
Tetrahydrate 0.01g/L.Fermentation liquid maintains pH 7.0 by the way that ammonium hydroxide is added, and 37 DEG C of tank temperature, speed of agitator 300-1300rpm, sends out
35% or more DO, air mass flow 1:1.5vvm are controlled during ferment.Access 1205 seed liquor of E.Coli BL21 (DE3) ST
OD600 is 0.68, and access amount is the 10% of fermentating liquid volume, and IPTG to final concentration 1mmol/ is added when fermentation liquid OD600 is up to 0.8
Hereafter L continues fermentation 15 hours, 25 DEG C of tank temperature to induce the expression of transaminase.By the way that 460g/ containing glycerol is added in fermentation process
L, yeast extract 150g/L, ammonium chloride 11.5g/L, ammonium molybdate tetrahydrate 0.04mg/L, ironic citrate 0.06mg/L it is molten
The growth of liquid maintenance culture.Culture is cooled to 4 DEG C of preservations after fermentation.
Fermentation liquid is centrifuged the conventional treatments such as (8000rpm, 10min), clasmatosis, freeze-drying, is prepared and turns
Adnosine deaminase polypeptide freeze-dried powder is simultaneously saved in -80 DEG C.
Embodiment 6 recombinates transaminase-catalyzed synthesis (R) -3- amino -4- (2,4,5- trifluorophenyl)-methyl butyrate (XT-4)
32.6kg substrate 3- carbonyl -4- (2,4,5- trifluorophenyl)-methyl butyrate, 132kg are added into 2000L reaction kettle
Isopropylamine hydrochloride, 0.55kg pyridoxime 5-phosphate (PLP), 550L DMSO, then to being added in kettle according to 5 method of embodiment
The recombination transaminase freeze-dried powder 29.5kg of preparation is warming up to 45 DEG C under nitrogen protection, and 4mol/L isopropylamine solution is added
The pH for adjusting reaction solution is 8.5.The pH for controlling reaction solution in reaction process by the way that 4mol/L isopropylamine solution is added is 8.5-
9.0, it is stirred to react 22 hours or so, until substrate content terminates reaction when being down to 3% or less.
It is operated after reaction terminating through centrifugation, extraction, decoloration etc., obtains product (R) -3- amino -4- (2,4,5- trifluoro-benzenes
Base)-methyl butyrate:1H NMR(CDCl3)d7.08(m,1H),6.94(m,1H),3.85(s,2H),3.77(s,3H),3.55(s,
2H);13C NMR(CDCl3)d 197.9,167.1,156.9,154.5,150.4,147.9,145.5,119.4,117.0,
105.5,52.4,48.3,41.9.It is analyzed through HPLC, determines the substrate transformation rate 97.6%, product ee 99.5%.
The concrete analysis condition of product ee value are as follows: Chiralpak AD-H chromatographic column (150mm × 4.6mm, 5um), flowing
Phase n-hexane-isopropanol (80:20, v/v);Detection wavelength 254nm, flow velocity 1mL/min, 30 DEG C of column temperature.
Embodiment 7 (R) -3- amino -4- (2,4,5- trifluorophenyl)-methyl butyrate (XT-4)
The addition 90ml dimethyl sulfoxide in reactor, 3- carbonyl -4- (2,4,5- trifluorophenyl)-methyl butyrate of 15g,
The isopropyl amine salt aqueous acid 90ml of pH=9.00 is added in stirring and dissolving, and crude enzyme liquid 120g and 0.08g phosphoric acid pyrrole is added and trembles
Aldehyde, 35 DEG C are stirred to react for 24 hours, are during which maintained between pH8.00-8.60 with isopropylamine solution, and acid adding terminates reaction, then 35 DEG C
Insulated and stirred 1h, is filtered to remove albumen, and water phase sodium hydrate aqueous solution tune pH to 10-11 is extracted with dichloromethane three times, closes
And the dry 2h of anhydrous sodium sulfate is added in methylene chloride, obtains product 14g, 99% or more purity after recycling methylene chloride.
Embodiment 8 (R) -3- t-butoxycarbonyl amino -4- (2,4,5- trifluorophenyl)-methyl butyrate (XT-5)
14.8g (R) -3- amino -4- (2,4,5- trifluorophenyl)-methyl butyrate (0.06mol) is weighed, 50ml bis- is dissolved in
In chloromethanes, 1ml triethylamine is added, 5 DEG C or less addition 14.4g di-tert-butyl dicarbonates (0.066mol) are warming up to room temperature
Reaction 15 hours is added 30ml water quenching and goes out, collects organic phase, and water phase is extracted with dichloromethane 2 times again, merges organic phase, is added
Anhydrous sodium sulfate is dry, rotates recycling design, obtains 18.7g white solid, yield 90%.
Embodiment 9 (R) -3- t-butoxycarbonyl amino -4- (2,4,5- trifluorophenyl)-butyric acid (XT-6)
By 17.4g (R) -3- t-butoxycarbonyl amino -4- (2,4,5- trifluorophenyl)-methyl butyrate (0.05mol), dissolution
In the in the mixed solvent of 120ml methanol and 60ml water, 6g sodium hydroxide (0.15mol) is added, is stirred to react at 40-45 DEG C
1.5 hours, revolving removed partial solvent, and it is 2-3 that 1N hydrochloric acid tune pH is added under ice bath, is extracted with ethyl acetate 3 times, is associated with
Machine phase, organic to be added to the dry 2h of anhydrous sodium sulfate with brine It 1 time, filtering rotates recycling design and obtains white solid
15.7g, yield 94%.
10 7- of embodiment [(3R) -3- t-butoxycarbonyl amino -1- oxo -4- (2,4,5- trifluorophenyl) butyl] -5,6,
7,8- tetrahydro -3- Trifluoromethyl-1,2,4- triazol [4,3-a] pyrazine (XT-7)
Under nitrogen protection, by 8.6g (R) -3- t-butoxycarbonyl amino -4- (2,4,5- trifluorophenyl)-butyric acid
Simultaneously piperazine hydrochloride (0.045mol) is dissolved in 50ml methylene chloride for (0.045mol), 10.28g trifluoromethyl triazole, ice
Bath is lower to be added 7.27g 1- hydroxy benzo triazole (0.054mol) and 10.3g 1- ethyl -3- (3- dimethylamino-propyl) phosphinylidyne
13.5g triethylamine is added dropwise in inferior amine salt hydrochlorate (0.054mol), and lower reaction 24 hours, reaction solution 50ml water washing 3 is stirred at room temperature
Secondary, organic anhydrous sodium sulfate that is added to is 2 hours dry, and recycling design obtains 20.9g, yield 91%.
11 Sitagliptin phosphate of embodiment
It weighs 10.14g XT-7 (0.02mol) and is dissolved in 100ml concentrated hydrochloric acid: the in the mixed solvent of ethyl alcohol (1:5), room temperature
It is stirred to react 4 hours, revolving removes ethyl alcohol, is neutralized, is extracted with ethyl acetate 3 times with sodium bicarbonate, merges organic phase, and nothing is added
Aqueous sodium persulfate is 2 hours dry, filtering, and after recycling design, under nitrogen protection, 80ml isopropanol and 10ml water is added, and 85 DEG C are stirred,
85% phosphoric acid of 3g is added, 85 DEG C are stirred to react 2 hours, are cooled to room temperature and are stirred for 10 hours, filtering drying obtains white Xi Talie
Spit of fland phosphate 9.09g, yield 90%.
12 Sitagliptin phosphate pilot scale of embodiment preparation
It weighs 5.1kg XT-7 (1mol) and is dissolved in 50L concentrated hydrochloric acid: the in the mixed solvent of ethyl alcohol (1:5), be stirred at room temperature anti-
It answers 4 hours, revolving removes ethyl alcohol, is neutralized, is extracted with ethyl acetate 3 times with sodium bicarbonate, merges organic phase, and anhydrous slufuric acid is added
Sodium is 2 hours dry, filtering, and after recycling design, under nitrogen protection, 45L isopropanol is added: the mixed solvent of water (8:1), 85 DEG C are stirred
It mixes, 85% phosphoric acid of 1.5kg is added, continue 85 DEG C and be stirred to react 2 hours, be cooled to room temperature and be stirred for 10 hours, filtering drying obtains
White Sitagliptin phosphate 4.71kg, yield 93%.
<110>Jiangsu Alpha Pharmaceutical Co., Ltd.
<120>a kind of recombination transaminase and its preparation method and application
<160> 5
<210> 1
<211> 978
<212> DNA
<213>artificial sequence
<220>
<223>encoding gene of transaminase mutant is recombinated
<400> 1
atggcctcca tggacaaagt ctttgccggc tacgccgccc gccaagcgat cctcgaatca 60
accgagacca ccaacccctt tgcgaagggt atcgcctggg tagaaggcga gctggtgccc 120
ctggcagagg cacgcattcc actgctcgac cagggcttca tgaaaagcga tctcacctac 180
gacgtgccct ccgtctggga cggccgcttc ttccggctag acgaccacat cacgcggctc 240
gaagccagct gcaccaagct ccggctgcga ctgccactcc cgcgcgacaa agtcaagcag 300
attctcgtcg agatggtgcg caagagcggc atccgcgacg cctttgtcga gctgatcgtg 360
acgcgcgggc tgaagggcgt gcgggggaca cgccccgagg acatcgtcaa caatctgtac 420
atgtttgtgc agccgtacgt gtgggtgatg gagccggata tgcagcgtgt cggcggcagc 480
gcggtcgtcg cccgcaccgt gcgccgggtg cccccgggtg ccatcgaccc aaccgtcaag 540
aacctgcaat ggggcgatct cgtgcgcggc atgttcgagg ctgcggatcg cggtgcaact 600
tatccgttct tgacggacgg agatgcccat ctcaccgaag gctctgggtt caatattgtg 660
ctcgtcaagg acggcgtgct gtacacacca gaccgtggtg tgctgcaggg cgtgacacga 720
aagagtgtta tcaatgcggc ggaagccttc gggattgaag tccgcgttga gtttgtgccg 780
gttgagctgg cgtaccgttg tgatgagatc tttatgtgta ccaccgctgg cggcatcatg 840
cctatcacta cgctggatgg gatgcccgtg aatggaggac agatcggtcc tattacgaag 900
aagatttggg atggatattg ggctatgcat tatgatgcgg cttacagctt cgagattgat 960
tataacgaga ggaactga 978
<210> 2
<211> 325
<212> PRT
<213>artificial sequence
<220>
<223>transaminase mutant is recombinated
<400> 2
Met Ala Ser Met Asp Lys Val Phe Ala Gly Tyr Ala Ala Arg Gln Ala
5 10 15
Ile Leu Glu Ser Thr Glu Thr Thr Asn Pro Phe Ala Lys Gly Ile Ala
20 25 30
Trp Val Glu Gly Glu Leu Val Pro Leu Ala Glu Ala Arg Ile Pro Leu
35 40 45
Leu Asp Gln Gly Phe Met Lys Ser Asp Leu Thr Tyr Asp Val Pro Ser
50 55 60
Val Trp Asp Gly Arg Phe Phe Arg Leu Asp Asp His Ile Thr Arg Leu
65 70 75 80
Glu Ala Ser Cys Thr Lys Leu Arg Leu Arg Leu Pro Leu Pro Arg Asp
85 90 95
Lys Val Lys Gln Ile Leu Val Glu Met Val Arg Lys Ser Gly Ile Arg
100 105 110
Asp Ala Phe Val Glu Leu Ile Val Thr Arg Gly Leu Lys Gly Val Arg
115 120 125
Gly Thr Arg Pro Glu Asp Ile Val Asn Asn Leu Tyr Met Phe Val Gln
130 135 140
Pro Tyr Val Trp Val Met Glu Pro Asp Met Gln Arg Val Gly Gly Ser
145 150 155 160
Ala Val Val Ala Arg Thr Val Arg Arg Val Pro Pro Gly Ala Ile Asp
165 170 175
Pro Thr Val Lys Asn Leu Gln Trp Gly Asp Leu Val Arg Gly Met Phe
180 185 190
Glu Ala Ala Asp Arg Gly Ala Thr Tyr Pro Phe Leu Thr Asp Gly Asp
195 200 205
Ala His Leu Thr Glu Gly Ser Gly Phe Asn Ile Val Leu Val Lys Asp
210 215 220
Gly Val Leu Tyr Thr Pro Asp Arg Gly Val Leu Gln Gly Val Thr Arg
225 230 235 240
Lys Ser Val Ile Asn Ala Ala Glu Ala Phe Gly Ile Glu Val Arg Val
245 250 255
Glu Phe Val Pro Val Glu Leu Ala Tyr Arg Cys Asp Glu Ile Phe Met
260 265 270
Cys Thr Thr Ala Gly Gly Ile Met Pro Ile Thr Thr Leu Asp Gly Met
275 280 285
Pro Val Asn Gly Gly Gln Ile Gly Pro Ile Thr Lys Lys Ile Trp Asp
290 295 300
Gly Tyr Trp Ala Met His Tyr Asp Ala Ala Tyr Ser Phe Glu Ile Asp
305 310 315 320
Tyr Asn Glu Arg Asn
325
<210> 3
<211> 978
<212> DNA
<213>Aspergillus terreus (Aspergillus terreus) NIH2624
<220>
<223>encoding gene of transaminase
<400> 3
atggcctcca tggacaaagt ctttgccggc tacgccgccc gccaagcgat cctcgaatca 60
accgagacca ccaacccctt tgcgaagggt atcgcctggg tagaaggcga gctggtgccc 120
ctggcagagg cacgcattcc actgctcgac cagggcttca tgcacagcga tctcacctac 180
gacgtgccct ccgtctggga cggccgcttc ttccggctag acgaccacat cacgcggctc 240
gaagccagct gcaccaagct ccggctgcga ctgccactcc cgcgcgacca ggtcaagcag 300
attctcgtcg agatggtggc caagagcggc atccgcgacg cctttgtcga gctgatcgtg 360
acgcgcgggc tgaagggcgt gcgggggaca cgccccgagg acatcgtcaa caatctgtac 420
atgtttgtgc agccgtacgt gtgggtgatg gagccggata tgcagcgtgt cggcggcagc 480
gcggtcgtcg cccgcaccgt gcgccgggtg cccccgggtg ccatcgaccc aaccgtcaag 540
aacctgcaat ggggcgatct cgtgcgcggc atgttcgagg ctgcggatcg cggtgcaact 600
tatccgttct tgacggacgg agatgcccat ctcaccgaag gctctgggtt caatattgtg 660
ctcgtcaagg acggcgtgct gtacacacca gaccgtggtg tgctgcaggg cgtgacacga 720
aagagtgtta tcaatgcggc ggaagccttc gggattgaag tccgcgttga gtttgtgccg 780
gttgagctgg cgtaccgttg tgatgagatc tttatgtgta ccaccgctgg cggcatcatg 840
cctatcacta cgctggatgg gatgcccgtg aatggaggac agatcggtcc tattacgaag 900
aagatttggg atggatattg ggctatgcat tatgatgcgg cttacagctt cgagattgat 960
tataacgaga ggaactga 978
<210> 4
<211> 978
<212> DNA
<213>artificial sequence
<220>
<223>primers F 1
<400> 4
ggggccatat ggcctccatg gacaaagtct tt 32
<210> 5
<211> 978
<212> DNA
<213>artificial sequence
<220>
<223>primer R1
<400> 5
gggccggatc ccgttataat caatctcgaa gc 32
Claims (10)
1. the recombination transaminase mutant that a kind of pyridoxime 5-phosphate relies on, it is characterised in that amino acid sequence such as SEQ ID
Shown in NO.2.
2. a kind of gene for encoding recombination transaminase mutant described in claim 1, it is characterised in that nucleotide sequence such as SEQ
Shown in ID NO.1.
3. a kind of expression vector containing gene as claimed in claim 2.
4. expression vector according to claim 3, it is characterised in that expression vector system pET21a.
5. a kind of for producing the genetic engineering bacterium of recombination transaminase mutant described in claim 1, it is characterised in that described
Contain gene as claimed in claim 2 in genetic engineering bacterium.
6. genetic engineering bacterium according to claim 5, it is characterised in that the host cell of the genetic engineering bacterium is large intestine
Escherichia (Escherichia coli) BL21 (DE3).
7. a kind of preparation method of recombination transaminase mutant described in claim 1, it is characterised in that include the following steps: to train
Genetic engineering bacterium described in any one of claim 5~6 is supported, the recombination transaminase mutant of recombinant expression is obtained.
8. according to the method described in claim 7, it is characterized in that carrying out work the method includes in the case where producing tank fermentation condition
Industryization prepares the step of recombination transaminase mutant;The production tank fermentation condition are as follows: DO35% or more, air mass flow
1:1.5vvm。
9. recombination transaminase mutant described in claim 1 is as catalyst in preparation (R) -3- amino -4- (2,4,5- trifluoro
Phenyl) application in-methyl butyrate.
10. a kind of synthetic method of sitagliptin, it is characterised in that reaction route is as follows:
Wherein the enzyme is recombination transaminase mutant described in claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611239147.1A CN106801043B (en) | 2016-12-28 | 2016-12-28 | A kind of recombination transaminase and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611239147.1A CN106801043B (en) | 2016-12-28 | 2016-12-28 | A kind of recombination transaminase and its preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106801043A CN106801043A (en) | 2017-06-06 |
CN106801043B true CN106801043B (en) | 2019-08-06 |
Family
ID=58985158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611239147.1A Active CN106801043B (en) | 2016-12-28 | 2016-12-28 | A kind of recombination transaminase and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106801043B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107384887B (en) * | 2017-07-05 | 2020-08-21 | 浙江工业大学 | Aminotransferase, mutant and application of aminotransferase to preparation of sitagliptin |
CN108586346B (en) | 2018-05-10 | 2019-10-01 | 北京富盛嘉华医药科技有限公司 | A kind of method that biocatalysis synthesizes sitagliptin and its intermediate |
CN108866021B (en) * | 2018-05-30 | 2021-06-08 | 浙江工业大学 | Transaminase mutant and application thereof in preparation of sitagliptin intermediate |
CN109486780B (en) * | 2018-11-14 | 2020-06-09 | 江南大学 | Omega-transaminase mutant with improved catalytic efficiency |
CN109486784B (en) * | 2018-11-30 | 2020-06-09 | 江南大学 | Omega-transaminase mutant capable of catalyzing sitafloxacin five-membered ring key intermediate |
EP4050100A4 (en) * | 2019-10-25 | 2022-11-09 | Asymchem Laboratories (Fuxin) Co., Ltd. | Transaminase mutant and use thereof |
CN111363732B (en) * | 2020-03-12 | 2023-05-23 | 卡柔恩赛生物技术湖北有限公司 | Transaminase mutant from aspergillus terreus NIH2624 and application thereof |
CN111549007B (en) * | 2020-04-07 | 2022-10-04 | 天津科技大学 | Transaminase TSTA, preparation method and application |
CN113149991A (en) * | 2020-12-31 | 2021-07-23 | 浙江美诺华药物化学有限公司 | Synthesis method of sitagliptin free base and sitagliptin phosphate monohydrate |
EP4273254A1 (en) | 2022-05-06 | 2023-11-08 | Enzymicals AG | Enzymatic method for preparing (r)-3-amino-4-aryl-butanoic acid derivatives |
CN118063351B (en) * | 2024-04-18 | 2024-06-28 | 北京元延医药科技股份有限公司 | Green synthesis of chiral beta amino acids using biological enzymes and immobilized aminotransferase used |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1796561A (en) * | 2004-12-20 | 2006-07-05 | 南京大学 | Recombined aminotransierase gene of glutamine of microbe, and preparation method |
CN103555739A (en) * | 2013-10-23 | 2014-02-05 | 绍兴文理学院元培学院 | Recombined microorganism glutamine transaminase gene and preparation method thereof |
CN104178536A (en) * | 2014-07-31 | 2014-12-03 | 洛阳华荣生物技术有限公司 | Biological preparation method for R-3-aminopiperidine |
CN104894148A (en) * | 2015-04-13 | 2015-09-09 | 浙江科技学院 | Omega-aminotransferase mutant gene and application thereof |
CN105441403A (en) * | 2015-12-08 | 2016-03-30 | 上海工业生物技术研发中心 | Aminopherase for producing L-2-aminobutyric acid |
CN106148296A (en) * | 2016-09-30 | 2016-11-23 | 南京工业大学 | Production method of recombinant glutamine transaminase |
-
2016
- 2016-12-28 CN CN201611239147.1A patent/CN106801043B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1796561A (en) * | 2004-12-20 | 2006-07-05 | 南京大学 | Recombined aminotransierase gene of glutamine of microbe, and preparation method |
CN103555739A (en) * | 2013-10-23 | 2014-02-05 | 绍兴文理学院元培学院 | Recombined microorganism glutamine transaminase gene and preparation method thereof |
CN104178536A (en) * | 2014-07-31 | 2014-12-03 | 洛阳华荣生物技术有限公司 | Biological preparation method for R-3-aminopiperidine |
CN104894148A (en) * | 2015-04-13 | 2015-09-09 | 浙江科技学院 | Omega-aminotransferase mutant gene and application thereof |
CN105441403A (en) * | 2015-12-08 | 2016-03-30 | 上海工业生物技术研发中心 | Aminopherase for producing L-2-aminobutyric acid |
CN106148296A (en) * | 2016-09-30 | 2016-11-23 | 南京工业大学 | Production method of recombinant glutamine transaminase |
Non-Patent Citations (5)
Title |
---|
A subfamily of PLP-dependent enzymes specialized in handling terminal amines;Davide Schiroli 等;《Biochimica et Biophysica Acta》;20150312;第1200-1211页 |
西他列汀的化学-酶法合成;徐中琦 等;《沈阳药科大学学报》;20141130;第31卷(第11期);第867-869页 |
转氨酶催化不对称合成芳香族 L-氨基酸;夏温娜 等;《生物工程学报》;20121125;第28卷(第11期);第1346-1358页 |
转氨酶在手性化合物合成中的研究进展;王潇莹 等;《沈阳药科大学学报》;20140430;第31卷(第4期);第313-323页 |
酶法制备手性芳香胺化合物的研究进展;郭跃平 等;《化工进展》;20101231;第29卷(第4期);第728-732页 |
Also Published As
Publication number | Publication date |
---|---|
CN106801043A (en) | 2017-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106801043B (en) | A kind of recombination transaminase and its preparation method and application | |
CN107384887B (en) | Aminotransferase, mutant and application of aminotransferase to preparation of sitagliptin | |
CN106995807B (en) | A kind of recombination transaminase and the preparation method and application thereof | |
CN106995808B (en) | A kind of recombination transaminase and its application | |
CN105018440A (en) | Aminotransferase and application thereof to synthesis of sitagliptin intermediate | |
CN109777813B (en) | transaminase-PLP co-immobilized enzyme and preparation and application thereof | |
US10005725B2 (en) | Method for producing pyrrole derivative, and intermediate thereof | |
CN112048485B (en) | Engineered transaminase polypeptide for preparing sitagliptin | |
CN108239618A (en) | Co-express genetic engineering bacterium and its application of cyclohexanone monooxygenase and dehydrogenation of isopropanol enzyme | |
CN107286164A (en) | Purposes of the compound in sitagliptin is prepared and the method for preparing sitagliptin | |
KR101519118B1 (en) | Highly stabilized epidermal growth factor mutants | |
CN106947772B (en) | Carbonyl reductase mutant and application thereof in preparation of chiral alcohol | |
CN117467733B (en) | High chiral purity sitagliptin and method for preparing same by using immobilized transaminase | |
CN104630125B (en) | Engineering bacteria and its application in the dihydroxy hecanoic acid t-butyl ester of (3R, 5S) 6 chlorine 3,5 is prepared | |
Fischer et al. | Isolation, expression and biochemical characterization of recombinant hyoscyamine-6β-hydroxylase from Brugmansia sanguinea–tuning the scopolamine production | |
CN112175971A (en) | Codon-optimized KRD gene and GDH gene and application thereof | |
CN112852789B (en) | Nitrilase mutant and application thereof | |
CN112143688B (en) | Construction and application of recombinant escherichia coli | |
CN111154735A (en) | Preparation method of ketene reductase and brivaracetam intermediate | |
CN106834244B (en) | Proline hydroxylase and application thereof | |
CN114277008B (en) | (R) -selective transaminase and application thereof | |
CN109180691B (en) | C3-aromatic pyrroloindole alkaloid and synthetic method thereof | |
CN103073554A (en) | Substituted pyrrole chromone compound | |
CN115975969A (en) | Transaminase and use thereof for the preparation of sitagliptin or an intermediate thereof | |
KR101934048B1 (en) | Flavin-Dependent Halogenase and Method for Preparing Halogenated Indole Compounds Using the Same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 223800 No.5 Yanshan Road, eco Chemical Technology Industrial Park, Suqian City, Jiangsu Province Patentee after: Jiangsu alpha Pharmaceutical Co.,Ltd. Address before: 224700 Yanshan Road, Suqian ecological Chemical Technology Industrial Park, Suqian City, Jiangsu Province Patentee before: ALPHA PHARMACEUTICAL Co.,Ltd. JIANGSU PROVINCE |
|
CP03 | Change of name, title or address |